Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of RO6870868 in Healthy Volunteers
- Conditions
- Healthy Volunteer
- Interventions
- Drug: placeboDrug: RO6870868
- First Posted Date
- 2013-07-30
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 60
- Registration Number
- NCT01911611
A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma
- First Posted Date
- 2013-07-29
- Last Posted Date
- 2019-05-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 46
- Registration Number
- NCT01910181
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳Sun Yet-sen University Cancer Center, Guangzhou, China
A Study to Collect Blood Samples From Patients With Spinal Muscular Atrophy for Biomarker Analysis
- Conditions
- Muscular Atrophy, Spinal
- First Posted Date
- 2013-07-29
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 36
- Registration Number
- NCT01910168
A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2013-07-23
- Last Posted Date
- 2019-10-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 979
- Registration Number
- NCT01905943
- Locations
- 🇧🇷
Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil
🇧🇷Hospital de Cancer de Barretos, Barretos, SP, Brazil
🇧🇷Hospital Amaral Carvalho, Jau, SP, Brazil
A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis
- First Posted Date
- 2013-07-22
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 52
- Registration Number
- NCT01904292
- Locations
- 🇺🇸
Hackensack University Medical Center; Pediatric Rheumatology, Hackensack, New Jersey, United States
🇺🇸Ann & Robert H. Lurie Children's Hospital of Chicago; Division of Rheumatology, Chicago, Illinois, United States
🇺🇸Cleveland Clinic Fndn, Cleveland, Ohio, United States
A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA)
- First Posted Date
- 2013-07-22
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 52
- Registration Number
- NCT01904279
A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"
- First Posted Date
- 2013-07-19
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 287
- Registration Number
- NCT01903993
- Locations
- 🇺🇸
Kaiser Permanente - Vallejo, Vallejo, California, United States
🇺🇸New York Oncology Hematology, P.C., Albany, New York, United States
🇺🇸Wenatchee Valley Hospital & Clinics, Wenatchee, Washington, United States
A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Genotype 1 Chronic Hepatitis C
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2013-07-19
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 283
- Registration Number
- NCT01903954
OPTIMA: An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Participants With Chronic Kidney Disease Stages 3 and 4 Not on Dialysis
- Conditions
- Anemia
- First Posted Date
- 2013-07-18
- Last Posted Date
- 2019-08-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 437
- Registration Number
- NCT01902628
- Locations
- 🇬🇷
Laiko General Hospital; Nephrology Div., Athens, Greece
🇬🇷General Hospital Of Athens G.Gennimatas; Nephrology, Athens, Greece
🇬🇷Uni Hospital of Alexandroupoli; Nephrology Dept., Alexandroupolis, Greece
An Observational Study of Induction Therapy With Fuzeon (Enfuvirtide) in Combination With Antiretroviral Drugs in Patients With HIV-1 Infection
- Conditions
- HIV Infections
- First Posted Date
- 2013-07-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 58
- Registration Number
- NCT01902615